SG11201900710YA - Increased fertility in bovine species - Google Patents

Increased fertility in bovine species

Info

Publication number
SG11201900710YA
SG11201900710YA SG11201900710YA SG11201900710YA SG11201900710YA SG 11201900710Y A SG11201900710Y A SG 11201900710YA SG 11201900710Y A SG11201900710Y A SG 11201900710YA SG 11201900710Y A SG11201900710Y A SG 11201900710YA SG 11201900710Y A SG11201900710Y A SG 11201900710YA
Authority
SG
Singapore
Prior art keywords
international
kansas
street
pct
shawnee
Prior art date
Application number
SG11201900710YA
Other languages
English (en)
Inventor
Jason Nickell
Daniel Keil
Albert Abraham
Warren Tully
Riekerink Richard Olde
Terry Settje
Leland Vickers
Stuart Nibbelink
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of SG11201900710YA publication Critical patent/SG11201900710YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201900710YA 2016-07-26 2017-07-25 Increased fertility in bovine species SG11201900710YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662366772P 2016-07-26 2016-07-26
PCT/US2017/043662 WO2018022583A1 (en) 2016-07-26 2017-07-25 Increased fertility in bovine species

Publications (1)

Publication Number Publication Date
SG11201900710YA true SG11201900710YA (en) 2019-02-27

Family

ID=59700165

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900710YA SG11201900710YA (en) 2016-07-26 2017-07-25 Increased fertility in bovine species

Country Status (21)

Country Link
US (1) US10933131B2 (pt)
EP (1) EP3490598A1 (pt)
JP (1) JP2019525935A (pt)
KR (1) KR102473370B1 (pt)
CN (1) CN109689095B (pt)
AR (1) AR109167A1 (pt)
AU (1) AU2017301528A1 (pt)
BR (1) BR112019001599A2 (pt)
CA (1) CA3031778A1 (pt)
CL (1) CL2019000185A1 (pt)
CO (1) CO2019000724A2 (pt)
CR (1) CR20190037A (pt)
DO (1) DOP2019000018A (pt)
IL (1) IL264380A (pt)
MX (1) MX2019001126A (pt)
NZ (1) NZ750181A (pt)
PE (1) PE20190566A1 (pt)
SG (1) SG11201900710YA (pt)
TW (1) TWI759317B (pt)
UY (1) UY37346A (pt)
WO (1) WO2018022583A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102514899B1 (ko) * 2022-03-04 2023-03-29 경북대학교 산학협력단 암소 번식 능력 개선용 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4812314A (en) * 1986-02-24 1989-03-14 Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization Lipid replacement therapy
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
TR200503031T2 (tr) * 1999-09-25 2005-09-21 University Of Iowa Research Foundation İmmünostimülatör nükleik asitler
JP2005532067A (ja) * 2002-07-03 2005-10-27 コーリー ファーマシューティカル グループ,インコーポレイテッド 刺激性免疫応答用の核酸組成物
AU2002953015A0 (en) 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
WO2006017857A2 (en) 2004-08-13 2006-02-16 The Trustees Of The University Of Pennsylvania Antibiotic resistance free dna vaccines
PT2429581E (pt) 2009-05-14 2015-11-02 Bayer Ip Gmbh Resposta imunitária reforçada em espécies aviárias
PL2654785T3 (pl) 2010-12-22 2019-09-30 Bayer Intellectual Property Gmbh Wzmocniona odpowiedź immunologiczna u gatunków wołowatych
CA2820499A1 (en) * 2013-06-18 2014-12-18 Bayer Intellectual Property Gmbh Enhanced immune response in bovine species
RU2530520C1 (ru) * 2013-08-02 2014-10-10 Государственное научное учреждение Научно-исследовательский ветеринарный институт Нечернозёмной зоны Российской Федерации Российской академии сельскохозяйственных наук Средство для оптимизации воспроизводительной функции коров
US10155950B2 (en) 2014-02-28 2018-12-18 Bayer Animal Health Gmbh Immunostimulatory plasmids
KR20180021874A (ko) 2015-06-26 2018-03-05 바이엘 애니멀 헬스 게엠베하 시토졸 dna 감시 분자의 조절 방법
AU2016304343A1 (en) 2015-07-31 2018-02-08 Bayer Animal Health Gmbh Enhanced immune response in aquatic species
KR20180036765A (ko) 2015-07-31 2018-04-09 바이엘 애니멀 헬스 게엠베하 돼지 종에서의 강화된 면역 응답성

Also Published As

Publication number Publication date
EP3490598A1 (en) 2019-06-05
KR102473370B1 (ko) 2022-12-05
PE20190566A1 (es) 2019-04-22
TW201817427A (zh) 2018-05-16
JP2019525935A (ja) 2019-09-12
CN109689095A (zh) 2019-04-26
CN109689095B (zh) 2023-10-03
BR112019001599A2 (pt) 2019-10-01
KR20190032434A (ko) 2019-03-27
WO2018022583A1 (en) 2018-02-01
CL2019000185A1 (es) 2019-06-28
CR20190037A (es) 2019-05-16
IL264380A (en) 2019-02-28
AU2017301528A1 (en) 2019-02-14
UY37346A (es) 2018-02-28
US10933131B2 (en) 2021-03-02
DOP2019000018A (es) 2019-07-31
CA3031778A1 (en) 2018-02-01
NZ750181A (en) 2023-02-24
US20190388538A1 (en) 2019-12-26
AR109167A1 (es) 2018-11-07
CO2019000724A2 (es) 2019-02-08
MX2019001126A (es) 2019-08-14
TWI759317B (zh) 2022-04-01

Similar Documents

Publication Publication Date Title
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201901747VA (en) Inhibitors of cellular metabolic processes
SG11201809064QA (en) Chimeric neurotoxins
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201906958TA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201804674UA (en) Heteroarylhydroxypyrimidinones as agonists of the apj receptor
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201900744SA (en) Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201809341PA (en) Mobile robot
SG11201811671XA (en) Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201910195WA (en) Methods for trapping and barcoding discrete biological units in hydrogel
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201908091QA (en) Aqueous anti-pd-l1 antibody formulation
SG11201809882XA (en) Pharmaceutical combinations for treating cancer